摘要
目的 探讨晚期非小细胞肺癌（NSCLC）患者血清肿瘤标志物水平与二线化疗客观疗效及生存时间的相关性。方法 选取四川省眉山市人民医院2011年11月—2013年11月收治的NSCLC 59例。34例给予多西他赛方案化疗,25例给予培美曲塞方案化疗。评估二线化疗客观疗效,并探讨血清肿瘤标志物水平与二线化疗客观疗效及生存时间的相关性。结果 2种二线化疗客观疗效比较差异无统计学意义（P〉0.05）。CEA＋CA153＋Cyfra21-1、CA125＋CA153＋Cyfra21-1阳性组合客观疗效低于阴性组合患者（P〈0.05）。CA153阳性患者中位无疾病生存时间短于阴性患者（P〈0.05）;CEA＋CA153＋Cyfra21-1阳性组合中位总生存期短于阴性组合患者（P〈0.05）。结论 NSCLC血清肿瘤标志物水平与二线化疗客观疗效及生存时间存在相关性,化疗前CEA＋CA153＋Cyfra21-1、CA125＋CA153＋Cyfra21-1检测阳性者客观疗效较差,CEA＋CA153＋Cyfra21-1检测阳性者OS较短。
Objective To investigate correlation between serum tumor marker level with objective effect and sur-vival time by second-line chemotherapy in patients with advanced non-small-cell lung carcinoma （ NSCLC） . Methods A total of 59 patients with NSCLC admitted during November 2011 and November 2013 were selected, and 34 patients were treated with Docetaxel chemotherapy, while 25 patients received Pemetrexed chemotherapy. Objective effects of sec-ond-line chemotherapy were evaluated, and correlations between serum tumor markers level with objective effects and sur-vival time by second-line chemotherapy were investigated in two groups. Results There was no statistically significant difference in objective curative effect by two kinds of second-line chemotherapy （P〉0. 05）. Objective effect value of pa-tients with positive CEA＋CA153＋Cyfra21-1 and CA125＋CA153＋Cyfra21-1 combination was significantly lower than that of patients with negative CEA＋CA153＋Cyfra21-1 and CA125＋CA153＋Cyfra21-1 combination （P〈0. 05）. Pro-gression-free survival time of patients with positive CA153 was significantly shorter than that of patients with negative CA153 （P〈0. 05）, and overall survival time of patients with positive CEA＋CA153＋Cyfra21-1 combination was shorter than that of patients with negative CA125 ＋CA153 ＋Cyfra21-1 combination （ P〈0. 05 ） . Conclusion Serum tumor marker level has a certain correlation with objective effect and survival time by second-line chemotherapy in patients with advanced non-small cell lung cancer. Before chemotherapy, patients with positive CEA ＋ CA153 ＋ Cyfra21-1 and CA125＋CA153＋Cyfra21-1 combination have worse objective curative effect, and patients with positive CEA＋CA153＋Cyfra21-1 have shorter overall survival time.
出处
《解放军医药杂志》
CAS
2017年第10期21-25,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
四川省科技厅攻关项目（2012SZ0089）
关键词
癌
非小细胞肺
肿瘤标记
生物学
抗肿瘤联合化疗方案
生存时间
Carcinoma
non-small-cell lung
Tumor markers
biological
Antineoplastic combined chemothera-py protocols
Survival time
